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CBG Effects on Breast Cancer Tissue Cells 
 
Abstract 
 Cannabigerol (CBG) is one of over 120 cannabinoids known that is produced by the 
Cannabis sativa plant and has become of recent therapeutic interest. Cannabinoids target 
primarily cannabinoid receptors 1 and 2 (CBR1/CBR2) and form ligand-receptor complexes that 
can activate many cell signal transduction pathways, explaining its wide range of beneficial 
effects across many conditions. Positive effects with the introduction of CBG have been shown 
in research for Huntington’s Disease, appetite-consumption levels, antibacterial efforts, and 
numerous other areas. The impact of breast cancer is seen highest in the female population, and 
is a condition still searching for the best therapeutic treatment. Cell death is commonly seen as 
an immune response to target tumor aggregates in breast cancer. This study looked specifically 
into the effect of CBG on two types of breast cancer cells (E3 luminal and EWD8 basal). In 
order to determine if the CBG could affect the cells, primers were designed for genes that were 
hypothesized in previous research to respond to CBD. The results were measured by a PCR. To 
measure the effects of cell proliferation and cell death, a MTT and cell trace assays were 
performed which suggested decreased proliferation and increased cell death. Based on these 
results, it appears that CBG slows proliferation and potentially induces necroptosis in human 
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Cannabigerol (CBG) is one of over 120 cannabinoids known that is produced by the 
Cannabis sativa plant. These various cannabinoids have beneficial properties that could be 
useful therapeutically. Cannabinoids target primarily cannabinoid receptors 1 and 2 
(CBR1/CBR2) and form ligand-receptor complexes that antagonize the alternative receptor 
complex. Many cell signal transduction pathways can be activated by CBG, explaining its wide 
effects across many conditions. Positive effects with the introduction of CBG have been shown 
in research for Huntington’s Disease, appetite-consumption levels, antibacterial efforts, and 
numerous other areas. The impact of breast cancer is seen highest in the female population, and 
is a condition still searching for the best therapeutic treatment. Cell death is commonly seen as 
an immune response to target tumor aggregates in breast cancer. This study looked specifically 
into the effect of CBG on two types of breast cancer cells (E3 luminal and EWD8 basal). In 
order to determine if the CBG could affect the cells, primers were designed for genes that were 
hypothesized in previous research to respond to CBD. The results were measured by a PCR. To 
measure the effects of cell proliferation and cell death, a MTT and cell trace assays were 
performed which suggested decreased proliferation and increased cell death. Based on these 
results, it appears that CBG slows proliferation and potentially induces necroptosis in human 
breast cancer cell lines.  
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Review of Relevant Literature 
Understanding CBG  
 This section will start the paper off understanding what Cannabigerol (CBG) is and the 
interactions that CBG has within a cell.  
 Cannabigerol (CBG) is one of over a hundred cannabinoids produced by the Cannabis 
sativa plant, which also produces ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) 
(Gugliandolo, Pollastro, Grassi, Bramanti, & Mazzon, 2018). These cannabinoids have shown to 
be beneficial anti-inflammatory and anti-bacterial agents (Gugliandolo et al., 2018). CBG has 
been brought to the forefront in the cannabinoid research of recent due to its potential benefits 
concerning human health. The current knowledge is limited in this area as these benefits are still 
being discovered; however, CBG shows promise in its positive effects across a wide range of 
conditions.  
Cannabigerol (CBG) is a non-psychotropic cannabinoid discovered in 1964 by Gaoni and 
Mechoulam (Gaoni, Mechoulam, 1964). In 1964, Gaoni and Mechoulam (1964) described 
Cannabis sativa L. as one of the most commonly used illicit narcotic drugs of that time. They 
were the first researchers to isolate the structure 3,4-trans-tetrahydrocannabinol, and partially 
synthesize the active constituent of cannabigerol (CBG) (Gaoni, Mechoulam, 1964). C. sativa 
originates from Central Asia and contains distinctive phytochemicals that further contribute to its 
therapeutic outcomes in various diseases (Zagozen, Cerenak, Kreft, 2020). The highest amount 
of cannabinoids within C. sativa are found within the “plants’ inflorescences and glandular 
trichomes” (Zagozen, Cerenak, Kreft, 2020).  Cannabinoids tend to bind and activate 
cannabinoid G-protein-coupled receptors-- CBR1 and CBR2 (sometimes denoted as 
CNR1/CNR2) (Navarro, Varani, Reyes-Resina, Sanchez de Medina et al., 2018). This ligand-
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receptor interaction forms complexes where an antagonist system between the two cannabinoid 
receptors occurs -- CBR2 complex blocks CBR1 mediated effects (Navarro, Varani, Lillo, 
Vincenzi et al., 2020). CBG also targets transient receptor potential channels (TRP channels), 
COX1/2 enzymes, and alpha-2 adrenergic receptors (Borrelli et al., 2013). These few sources 
indicate the potential of CBG within therapeutic research, yet highlight the lack of concrete 
results and limited studies.  
 
Prior CBG Research 
 Cannabigerol has been used in a plethora of research recently as its beneficial properties 
have become more apparent. Aqawi, Gallily, Sionov, Zaks, Friedman, and Steinberg (2020) 
studied cannabigerol’s effects on prokaryotic Vibrio harveyi, as much of CBG’s limited studies 
have been on eukaryotic cells. These researchers hypothesize CBG as an anti-biofilm and anti-
quorum sensing catalyst for V. harveyi, preventing cell-to-cell communication and environment 
sensing (Aqawi et al., 2020). Their results supported their hypothesis as a potential anti-biofilm 
agent inhibiting quorum sensing with the use of DNA quantification, quantitative real-time PCR, 
and motility assays (Aqawi et al., 2020). Cannabinoids have been shown to have antimicrobial 
activity against certain species of gram-positive bacteria (Aqawi, Sionov, Gallily, Friedman, 
Steinberd, 2021). Using scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM), Aqawi et al. (2021) saw “intracellular accumulation of membrane portions” 
and swollen Streptococcus mutans after CBG introduction. Staining emphasized CBG’s 
alterations to the membrane’s structure and polarization state (Aqawi et al., 2021). Their 
hypothesis was supported that CBG exerts antibacterial properties against Streptococcus mutans 
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by increasing the bacteria’s membrane permeability and subsequently preventing pH changes to 
the cell (Aqawi et al., 2021).  
Within non-human research, rats/mice are readily used within CBG studies. Brierley, 
Samuels, Duncan, Whalley, and Williams (2016) study possible impacts on food intake with 
CBG introduction in rat populations. Cannabinoids devoid of the normal appetite-stimulating 
properties of THC still give rise to differences in eating behavior when introduced to eukaryotic 
organisms like rats (Brierley et al., 2016). The researchers observed feeding patterns through 
neuromotor tolerability testing, and regular meal monitoring. A range of 30-120 mg/kg of CBG 
doses were introduced to one experimental group, or a placebo was introduced to the control 
group; the researchers discovered the range of 120-240 mg/kg of CBG as the most impactful 
dosage, doubling the amount of food eaten by the rats (Brierley et al., 2016). This research 
showcases CBG’s potential hyperphagic effects for the first time, with the direct relationship 
seen between food consumption and CBG dosage introduction (Brierley et al., 2016). Various 
plant-derived cannabinoids like CBG are used frequently in experimental models showing 
neuroprotective potential for Huntington’s disease (HD) (Valdeolivas, Navarrete, Cantarero, 
Bellido, Munoz, Sagredo, 2015). CBG has already been shown to improve motor skills and 
antioxidant defense levels in mice, inspiring Valedolivas et al. (2015) to further understand the 
neuroprotective capabilities of the cannabinoid. This research utilized histological analyses and 
oxidative stress systems to discern that a series of genes are linked to HD and these genes’ 
expression was partially normalized with CBG treatment introduction (Valdeolivas et al., 2015). 
Gene expression improved for the brain-derived neurotrophic factor and insulin growth factor-1 
genes, but was reduced in the genes responsible for mutant huntingtin aggregates (Valdeolivas et 
al., 2015). Their hypothesis was partially supported, and the research opens up the possibility for 
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CBG therapy in treating neurodegenerative conditions like Huntington’s Disease (Valedolivas et 
al, 2015).  
Navarro, Varani, Reyes-Resina et al., (2018) study a different aspect of CBG in terms of 
its interactions with CBR1 and CBR2 receptors, and the subsequent effects seen from each 
complex activation (Navarro et al., 2018). This research is applicable to my research presented in 
this paper. Their team discovered that CBG showed competitive binding favoring CBR2 but not 
CBR1 in living CHO cells transfected with cDNA of human CBR1/2 receptors (Navarro et al., 
2018). Further ERK phosphorylation, dynamic mass redistribution, and Beta 2 Arrestin 
recruitment assays showed CBG as a partial agonist for CBR2 (Navarro et al., 2018). The 
downstream cellular cascade of CBG on CBR1 still remains an open research topic, but this 
paper is successful in showing the partial potential of CBG regulating CBR2’s signal cascade 
Navarro et al., 2018). Understanding CBG’s interactions with and effects on the 
endocannabinoid receptors is essential in planning experiments targeting these receptors. These 
sources show the wide range of possibilities in using CBG therapeutically, which drives my 
curiosity towards CBG’s effects on breast cancer tissue cells.  
 
Breast Cancer Tissue Cells 
 Breast cancer is one of the most fatal cancer-related conditions among women across the 
world (S. Aziz, M. Aziz, 2012). There are 5 distinct subtypes of breast cancer, two of which are 
the luminal subtypes and basal-like subtypes (Badve, Turbin, Throat, Morimiya et al., 2007). 
Luminal cell subtypes make up >70% of tumors seen in breast cancer patients, primarily 
containing estrogen/progesterone receptors and cytokeratin (Haughian et al., 2012). Luminal 
cancers typically have a positive prognosis, but hormone resistance within recurring tumors is 
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highly likely (Haughian et al., 2012). Basal cell subtypes are defined by the presence/absence of 
estrogen/progesterone receptors, EGF1, EGFR, and/or CK5 (Haughian et al., 2012). Both cell 
types were used in the following research. Many major signaling pathways, like the one attached, 
show the complexity involved in 
understanding breast cancer and in targeting 
the best receptors for the patient’s prognosis 
(Aziz, Aziz, 2012). In rats and mice, normal 
adaptive immune responses against these 
epithelial breast cancer cell types lead to an 
outgrowth of T-cells and HER2 antigen loss 
(Stein et al., 2019). Recognizing potential 
targets and indicators of breast cancer is still 
being investigated. Minimal work has been 
done toward CBG implementation in 
combating some of the detrimental impacts 
of breast cancer.  
 
Cell Death & Necroptosis  
One method of therapeutics that are used to encourage our immune system to attack and 
eliminate cancer cells is immunogenic cell death (ICD) (Kaur, Johnson, Northcote-Smith, Lu, 
2020). ICD allows the dying cancer cells to send protein signals out, stimulating tumor-
associated immune cells to target invading tumors (Kaur et al., 2020). ICD is capable of being 
induced in breast cancer stem cells, and stem cells that have sustained through ICD have 
Aziz, S. W., & Aziz, M. H. (2012). Major signaling pathways 
involved in breast cancer. (pp. 47-64). New York, NY: 





potential as a vaccine to further initiate a stronger immune response (Kaur et al., 2020). This 
induction process is an insufficiently researched area of immunotherapy currently, but Kaur et 
al., (2020) reports of a “copper II complex (made of Schiff base and polypyridyl ligands)” as the 
first capable metal complex to induce ICD in these breast cancer stem cells (Kaur et al., 2020).  
Another potential immune response breast cancer cells could induce is necroptosis, one 
type of programmed cell death associated with caspase 8 kinase, receptor-interacting 
serine/threonine kinase 1 (RIPK1), and RIPK3 (Sun, Pan, Ma, Chen, Zhao, Liu, 2021). Sun et al. 
(2021) investigates if 3-bromopyruvate (3-BP), an inhibitor for glycolysis, induces a form of cell 
death and if it affects breast cancer cell proliferation (Sun et al., 2021). 3-BP treatment was 
shown to inhibit cell proliferation in two cell types, causing a significant antitumor decrease 
correlated with necroptotic protein PpM1B (Sun et al., 2021). The preceding research relating 
breast cancer cell types and various forms of cell death indicate multiple potential pathways for 
targeting in treatment.  
 Following this review of relevant literature is my CBG research on breast cancer tissue 
cells from both subtypes. I investigated the effects of CBG on cell proliferation and subsequent 









This research was conducted in a team with Morgan Orand and Taylor Lupica, and utilizes 
procedures from UNCO’s Cell/Molecular Lab course BIO442. 
Research Question:  
How will CBG media affect the gene expression of CNR1, CNR2, Ripk1, and MLKL? How will 
cell proliferation be impacted? In what way will cell death occur? 
Hypothesis:  
We predict an overall increase in CNR1, CNR2, Ripk1, and MLKL gene expression because the 
cannabinoid ligands present in the CBG should bind and activate downstream signaling of the 
CNR1 and CNR2 receptors within breast cancer cell lines.  
We predict decreased breast cancer cell proliferation, and increased necroptosis cell death with 
introduction of cannabinoid binding from CBG agar due to CNR1 and CNR2 activation and 
dimerization, ultimately activating the downstream cell signaling pathway. This activated 





Figure 1 Kisková, T., Mungenast, F., Suváková, M., Jäger, W., & Thalhammer, T. (2019). Future Aspects for 
Cannabinoids in Breast Cancer Therapy. International journal of molecular sciences, 20(7), 1673. 
https://doi.org/10.3390/ijms20071673 
Cell death frequency increases with the activation and dimerization of CNR2 and CNR1. This 
research aims to activate these pathways with the introduction of cannabinoids in CBG agar.  
 
Figure 2 Dhuriya, Y. K., & Sharma, D. (2018). Necroptosis: A regulated inflammatory mode of cell death. Journal 
of Neuroinflammation, 15(1), 199. doi:10.1186/s12974-018-1235-0 
14 
 




Methods:   
Culture of Experimental Cell Lines 
Control: E3 Cell lines on MEM media 
Experimental: E3 cell lines on MEM media with CBG 
● Concentration 1: 2 micromolar  
● Concentration 2: 20 micromolar  
● Concentration 3: 200 micromolar 
We cultured E3 (luminal) cell line cells in T25 flasks for assays. Cells were split to promote 
growth by first removing E3 cells from original flask to pellet. The cells were centrifuged at 
300rpm for 15 minutes. 5mL of PBS was added after the first supernatant was removed, and the 
cells were centrifuged again, but at 400rpm for 10 minutes. The supernatant was removed again, 
and this was repeated once more. After the third supernatant had been removed, 1.5 mL of 
trypsin was added and allowed to incubate to interrupt the cell’s natural adhesion to the flask. 
The trypsin was removed, and 1mL of MEM was added to the cells, then the sample was 
centrifuged at 400rpm for 5 minutes. 4mL of cells were put into one flask, and the other 4mL 
were put in a different flask.  
The cells were split into experimental and control flasks. The control flask was left untreated. 
Three different doses of CBG were tested in this experiment-2uM, 20uM, and 200 uM. The 
vehicle for this drug had 10 uL Tween-80, 37.5 uL DMSO, and 750 uL PBS. Cells were counted 
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with a hemocytometer on 1st, 3rd, and 7th days to evaluate effects on proliferation after enough 
cells had grown.  
CellTrace Violet Cell Proliferation Kit (CellTrace™ Violet Cell Proliferation Kit Procedure) 
This assay was used to monitor numbers of cell divisions of proliferating cells using 
diluted dye. With flow cytometry, different cells have different peaks on the graph assuming the 
cells have various numbers of cell divisions. Cells from both the experimental and control flasks 
were spun down, and the supernatant was removed, leaving a pellet. CellTrace Violet (1:1000 
dilution) staining solution was added the same day, and cells were resuspended in solution. The 
flasks were incubated at 37 Degrees Celsius for 20 minutes in the dark. Complete culture 
medium (MEM) was mixed in and the cells were incubated again at 37 Degrees Celsius for 5 
minutes. Cells were spun down again, supernatant removed leaving a pellet, and resuspended in 
fresh, pre-warmed media. Flow cytometer analysis was performed 4-5 days after the addition of 
the dye and treatments. This was repeated 3 different times.  
 
MTT Assay  
The MTT assay was used to measure cellular metabolic activity as an indicator of cell 
viability, proliferation, and cytotoxicity. This assay was set up in triplicate according to Table 1. 
The colorimetric assay is based on the reduction of yellow tetrazolium salt into purple formazan 
crystals by metabolically active cells. Only E3 cells were plated in a 96 well dish, and 100,000 
cells were plated in each well. The cells were left 1 week in the incubator (37 C) and then 45 ul 
of media and 5 ul of MTT was added to each well. They were incubated for 4 hours. After 4 
hours, purple crystals formed and were completely dissolved in solubilization solution. The 
absorbance reading was taken from the plate and the data was normalized for analyzing the 


































Table 1. Treatment groups in MTT Assay  
RNA Isolation  
We isolated total RNA from the E3 and EWD8 cell lines without CBG treatment 
following protocol from Pure Link Mini Kit. This was done very carefully as RNA is fragile and 
prone to degradation by RNases. Once the E3 and EWD8 RNA were isolated, we tested to see if 
it was pure enough to continue transforming the RNA to cDNA. Using a Nano-drop 
spectrophotometer that was first blanked, a sample may be applied, and readings can be taken. 
The readings observed come from the ratio of absorbance at 260nm and 280nm. A ratio of ~2.0 
is considered acceptable for the purity of RNA.  
cDNA Synthesis  
 The next step was ensuring the RNA quality, and electrophoresis on a denaturing agarose 
gel. The denaturing gel was prepared with 1% agarose water, 10x MOPS buffer and 
formaldehyde. The RNA samples were mixed with formaldehyde- containing loading dye and 
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were denatured at 65 degrees Celsius for five minutes. We performed a native (non-denaturing) 
agarose gel electrophoresis which allowed us to judge the overall integrity of a totally RNA 
preparation by inspection of the 28S and 18S rRNA bands. The secondary structure of RNA 
altered the migration pattern in the gel so that it did not migrate according to true size. The intact 
RNA should have a sharp 28S and 18S rRNA band.  
Primer Design 
 Primers were designed to amplify a 100-200 bp fragment of each gene of interest. Two 
primers were designed for each gene (a forward and a reverse) corresponding to the 5’/3’ 
boundary (respectively). Using the basic rules of thumb for primer design, and NCBI, mRNA 
sequences of each gene were obtained and run through Primer Blast. The following were the 









Primers were then ordered and used for future assays. 
PCR 
Once the RNA was found to be intact, it was then synthesized into cDNA in order to be 
stored and manipulated to be used in PCR. To synthesize the RNA, 1 ug of RNA was put in a 
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nuclease free PCR tube and the volume was adjusted to 11ug with the autoclaved DEPC treated 
water. 1 ul dNTPs and 2 uL anchored oligo dT22 were added and spun down, denaturing the 
RNA. Afterwards, 4 ul 5X First strand buffer, 1.2ul DEPC-treated water, 1ul DTT, 05.uL 
RNase-out and 0.3 ul Superscript III were added to the previous PCR tube. The tube was spun 
down again and ready for PCR and storage. This was done for both the E3 and EWD8 cell 
lines.  With the obtained cDNA and the previously designed primers (CNR1, CNR2, RIPK1, 
MLKL) a polymerase chain reaction was performed. Primers were diluted depending on their 
‘nmol’ value (ex. 19.34 nmol= 193.4 uL of water added). There was a total of 11 PCR tubes. 
Eight experimental PCR tubes contained 18 ul of the master mix (1 ul E3 or EWD8 cDNA, 10 ul 
GoTaq and 7 ul nuclease free water) and 1ul of the forward primer and 1 ul of the reverse primer. 
The negative control contained 18 ul master mix without cDNA and with one (any) of the 
primers-- 1 ul forward and 1 ul reverse. Two known positives were also introduced that had beta-
actin forward and reverse primers (following the same amounts as the test PCR tubes).  All tubes 
were run in the thermocycler: A. 1 cycle at 94 C for 2 minutes  B.  40 cycles of: 1. Denaturing: 
94C for 30 seconds 2. Annealing  52-68 C for 30 seconds 3. Elongation 72 C for 30 seconds. 
After 40 cycles, there was a 10-minute extension for final elongation at 72 C, then a hold at 12 C. 
Once this was done, 10 ul of each of the 11 samples were mixed with 2 ul of sybr green dye and 
loaded into a 1% agarose gel. The gel then ran at 100 volts for 45 minutes. The gel should 
hopefully show bands at all of the different primers, indicating that the primers worked and that 
the genes we targeted were present. Once these results were obtained, different concentrations of 
CBG (2mM, 20 mM, and 200 mM) were added to the cDNA of the E3 and EWD8 cell lines to 









Figure 3 MTT Assay Results (Normalized) - Micromolar dosages of CBG 
  
The MTT assay assessed the viability of the cells when introduced to different amounts 
of CBG. The data that was collected was normalized, meaning it was compared to a series of so-
called “normal forms” in order to reduce data redundancy and improve data integrity. 
Normalization of the data made sure that all the data looked and read the same way across all 
different doses of CBG. According to Figure 3, 2 uM allied for the least amount of cells to 
survive and 20 uM allowed for the most amount of cells to survive when treated.  Unfortunately, 
no statistic could be run on this data because time only allowed for one trial of the MTT assay to 
take place. To confirm these results and draw conclusions, the MTT assay would need to be 
repeated, and combined with the other assays. From this data, we may begin to hypothesize that 
2 uM may be the most effective of increasing death/decreasing viability in E3 and EWD8 human 





The PCR gave some very interesting results 
as we had expected all of the genes we 
hypothesized to be expressed, but found that only 
the CNR 2 gene was expressed. The data also 
suggests that the expression of CNR2 is greater in 










Table 2.  Raw Data of Concentrations of CBG vs Intensity of Dye (Three trials) 
 
 












The cell trace data showed decreasing intensity of dye with increased dosages of CBG 
(Figure 5). Further cell proliferation statistical analysis was not possible due to COVID-19, but 
we predicted that a lower intensity indicates greater rates of cell proliferation which was shown 
to be accurate from the results. 200uM of CBG saw greater intensity between the three trials 










Figure 5 Cell Trace-Concentration of CBG vs Intensity Dye (Three trials) 
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Discussion of Research 
 Based on the findings from the literature and the research conducted, CBG has potential 
as a therapeutic agent in helping slow cell proliferation in breast cancer cell lines. CBG has been 
useful in many other conditions and is on the rise in the research industry as more benefits are 
discovered. There are large gaps in exact signal transduction pathways affected with CBG, but 
research like the one conducted help contribute to the understanding of CBG’s targets.  
The slowing of cell proliferation and preferential binding of CNR2 did not surprise me. 
The review of relevant literature supports the results of competitive binding toward CNR2 than 
CNR1 (Navarro et al., 2018). Better gene targets could have been chosen to further emphasize 
this, like the ones listed in other research studies studying eukaryotic cells. Cell necroptosis was 
unable to be investigated due to the COVID-19 pandemic, but a western blot and necroptosis 
assay would be useful in determining the exact immune response seen between CBG and breast 
cancer cells.  
In conclusion, CBG appears to slow the proliferation of human breast cancer cells, 
activate CNR2, affect cells at different doses, and affect the E3 and EWD8 cell lines in different 
ways. This research indicates there is potential to help lessen tumor severity in breast cancer with 
CBG, and demands further investigation be done with this cannabinoid. Other studies should be 
conducted to test for the presence and activation of CNR1 in these cells. In addition, more 
research should be done to investigate the inflammatory effects of this drug on the breast cancer 
cell subtypes to further understand side effects associated. This is just the surface of CBG’s 
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